Canopy Homolog 2 as a Novel Molecular Target in Hepatocarcinogenesis.
CNPY2
hepatocarcinogenesis
human
mice
molecular target
prognostic marker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Jul 2021
19 Jul 2021
Historique:
received:
18
06
2021
revised:
09
07
2021
accepted:
13
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
In the present study, the role of a novel protein involved in neurite development and endoplasmic reticulum (ER) stress, canopy homolog 2 (CNPY2), was investigated in mouse and human hepatocarcinogenesis. Firstly, a sensitive quantitative and qualitative detection of protein expression using QSTAR Elite LC-Ms/Ms was performed for the analysis of lysates of microdissected hepatocellular altered foci (AF), adenomas (HCAs), carcinomas (HCCs) and peri-tumoral livers from C57Bl/6J mice treated with diethylnitrosamine (DEN) and then maintained for 27 or 38 weeks on basal diet. Significant overexpression of 18.5 kDa CNPY2 processed form was demonstrated in AF, HCAs and HCCs, while low expression was observed in the livers of DEN-treated and control mice. Furthermore, CNPY2 elevation in AF and tumors was coordinated with accumulation of numerous cytoskeletal proteins, including cytokeratins 8 and 18, actin, non-muscle myosin and septin 9 and those involved in ER and mitochondrial stresses such as calreticulin, prohibitins 1 and 2 and YME1-like-1. Knockdown of CNPY2 in Huh7 and HepG2 human liver cancer cells resulted in significant suppression of cell survival and invasive potential, inhibition of cyclin D1, induction of p21
Identifiants
pubmed: 34298825
pii: cancers13143613
doi: 10.3390/cancers13143613
pmc: PMC8306219
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports and Science and Technology of Japan, Grant-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan
ID : 19710167, 24501354
Références
Int J Mol Sci. 2016 Nov 15;17(11):
pubmed: 27854312
Am J Pathol. 2016 Apr;186(4):1015-24
pubmed: 26835537
Mol Oncol. 2009 Aug;3(4):321-38
pubmed: 19577966
Cancer Treat Res. 2004;119:217-37
pubmed: 15164880
Proteomics. 2007 May;7(10):1564-74
pubmed: 17443845
Ann Surg. 2007 Jun;245(6):909-22
pubmed: 17522517
Nat Genet. 2002 Aug;31(4):339-46
pubmed: 12149612
Biochem Biophys Res Commun. 2017 Apr 1;485(2):267-271
pubmed: 28235487
Cancer Sci. 2012 Jul;103(7):1363-9
pubmed: 22494014
Eur Heart J. 2015 Oct 1;36(37):2530-40
pubmed: 26160001
J Vet Med Sci. 2013;75(5):633-8
pubmed: 23229540
Electrophoresis. 2000 May;21(9):1787-813
pubmed: 10870966
Aging (Albany NY). 2017 Nov 13;9(11):2334-2351
pubmed: 29135454
Iran J Basic Med Sci. 2019 Oct;22(10):1198-1202
pubmed: 31998463
Science. 2002 Jul 5;297(5578):63-4
pubmed: 12098689
Methods Mol Med. 2006;120:65-75
pubmed: 16491595
J Biol Chem. 2003 Sep 12;278(37):35412-20
pubmed: 12826659
Cell Mol Life Sci. 2005 Jun;62(11):1260-6
pubmed: 15905959
J Proteome Res. 2005 Nov-Dec;4(6):2062-9
pubmed: 16335951
Curr Opin Gastroenterol. 2004 May;20(3):248-53
pubmed: 15703649
Electrophoresis. 1999 Apr-May;20(4-5):689-700
pubmed: 10344234
Hybridoma (Larchmt). 2008 Aug;27(4):285-9
pubmed: 18707546
Toxicol Appl Pharmacol. 2009 Jul 1;238(1):71-9
pubmed: 19409407
J Clin Oncol. 2002 Mar 15;20(6):1527-36
pubmed: 11896101
Mol Cancer. 2004 Dec 03;3(1):35
pubmed: 15579197
Carcinogenesis. 2006 Oct;27(10):2018-27
pubmed: 16621886
Hum Pathol. 2017 Aug;66:115-125
pubmed: 28603065
Toxicol Sci. 2011 Jan;119(1):61-72
pubmed: 20935162
Toxicol Appl Pharmacol. 2010 Jan 1;242(1):47-55
pubmed: 19796649
PLoS One. 2014 Nov 13;9(11):e111370
pubmed: 25393402
Nat Struct Mol Biol. 2017 Oct;24(10):834-839
pubmed: 28869608
Toxicol Appl Pharmacol. 2013 Dec 1;273(2):390-400
pubmed: 24090815